4Basebio

4Basebio Inventory

The Inventory of 4Basebio (4BB.L) as of Oct 21, 2026 is 657,000.00 GBP. In the previous year, Inventory was 374,000.00 GBP — a change of 75.67% (higher).

Inventory

657,000.00GBP

YoY

75.67%

Last updated:

Inventory of 4Basebio is 2025 657,000.00 GBP. Inventory of 4Basebio was 2024 374,000.00 GBP. It decreases by 75.67% higher compared to the previous year.

The 4Basebio Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2019
102,000.00 GBP
Jan 1, 2020
131,000.00 GBP
Jan 1, 2021
156,000.00 GBP
Jan 1, 2022
133,000.00 GBP
Jan 1, 2023
332,000.00 GBP
Jan 1, 2024
374,000.00 GBP
Jan 1, 2025
657,000.00 GBP
The 4Basebio Inventory history
YEARInventoryYoY
657,000.00GBP+75.67%
374,000.00GBP+12.65%
332,000.00GBP+149.62%
133,000.00GBP-14.74%
156,000.00GBP+19.08%
131,000.00GBP+28.43%
102,000.00GBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

4Basebio Stock analysis

What does 4Basebio do? 4basebio Plc develops advanced therapy medicinal products using synthetic DNA and non-viral delivery platforms for cell and gene therapies, DNA vaccines, and mRNA solutions. The company manufactures application-specific synthetic DNA for research, therapeutic, and pharmacological use, while also creating non-viral vectors for efficient payload delivery. Its technology enables the production of synthetic DNA constructs, mRNA, and vectors for cell and tissue-specific delivery, targeting applications such as AAV and Lentivirus viral vectors, mRNA vaccines, genome editing, and DNA vaccines. The company focuses on exploiting intellectual property in cell and gene therapies and DNA vaccines to drive innovation and commercialization. The primary customers for 4basebio Plc's products include research institutions, biotechnology firms, and pharmaceutical companies seeking advanced therapeutic solutions. These entities purchase synthetic DNA constructs, non-viral delivery vectors, and specialized DNA-based products for use in developing cell and gene therapies, DNA vaccines, and mRNA therapeutics. The company's offerings are tailored to support the development of safe and effective treatments across multiple therapeutic areas. 4basebio Plc's revenue streams are derived from the manufacturing and supply of synthetic DNA products, non-viral delivery platforms, and intellectual property licensing. The company generates income through the sale of application-specific synthetic DNA for research and therapeutic applications, as well as the development of delivery vectors for targeted therapies. By leveraging its proprietary technology in DNA synthesis and payload delivery, 4basebio Plc positions itself as a key provider of essential components for next-generation biologics and vaccines. 4Basebio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 4Basebio stock

Inventory of 4Basebio is 657,000.00 GBP in 2025.

Inventory of 4Basebio changed from 374,000.00 GBP to 657,000.00 GBP, representing a 75.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory 4Basebio since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's 4Basebio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — 4Basebio

All Key Metrics — 4Basebio